# Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.

Study · id `cardio:ct-nct03773822` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03773822](<https://clinicaltrials.gov/study/NCT03773822>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03773822

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 380 participants.

## Technical summary

Registry record NCT03773822. Randomized; double masking; primary purpose treatment. Start 2019-04-19 (actual); primary completion 2023-04-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 380 participants (enrolled count; ClinicalTrials.gov record NCT03773822, source copy `cardio:ctgov-nct03773822-2026-05-19`, retrieved 2026-10-31)
- Started: 2019-04-19 (actual) (ClinicalTrials.gov record NCT03773822, source copy `cardio:ctgov-nct03773822-2026-05-19`, retrieved 2026-10-31)
- Primary completion: 2023-04-05 (actual) (ClinicalTrials.gov record NCT03773822, source copy `cardio:ctgov-nct03773822-2026-05-19`, retrieved 2026-10-31)
- Completion: 2023-04-05 (actual) (ClinicalTrials.gov record NCT03773822, source copy `cardio:ctgov-nct03773822-2026-05-19`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT03773822, source copy `cardio:ctgov-nct03773822-2026-05-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03773822-2026-05-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.
- Acronym: COCCA
- Condition: Cardiogenic Shock
- Intervention (Combination product): Hydrocortisone + Flucortac
- Intervention (Other): Placebo
- Lead sponsor: CMC Ambroise Paré
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)

## Provenance

Content hash: 9b49004194fb4f6adf6e8c2802f8382acdaa08280b12344dc8ee9576d283fc06
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
